Drugs that prolong QT interval as an unwanted effect: assessing their likelihood of inducing hazardous cardiac dysrhythmias.
about
Antagonist action of progesterone at σ-receptors in the modulation of voltage-gated sodium channelsThe use of pharmacokinetic and pharmacodynamic data in the assessment of drug safety in early drug developmentCardiac arrest and ventricular arrhythmia in patients taking antipsychotic drugs: cohort study using administrative data.Position of aromatic residues in the S6 domain, not inactivation, dictates cisapride sensitivity of HERG and eag potassium channels.Congenital long QT syndromes and Brugada syndrome: the arrhythmogenic ion channel disorders.Translational potential of a mouse in vitro bioassay in predicting gastrointestinal adverse drug reactions in Phase I clinical trials.Hydrogen sulfide suppresses outward rectifier potassium currents in human pluripotent stem cell-derived cardiomyocytes.Psychotropic drugs and the ECG: focus on the QTc interval.Investigation of the potential of clozapine to cause torsade de pointes.The role of investigative molecular toxicology in early stage drug development.Discovery of a Potent and Selective ROMK Inhibitor with Pharmacokinetic Properties Suitable for Preclinical Evaluation.ICH S7B draft guideline on the non-clinical strategy for testing delayed cardiac repolarisation risk of drugs: a critical analysis.Identifying the translational gap in the evaluation of drug-induced QTc interval prolongation.Functional consequences of methionine oxidation of hERG potassium channels.Exploratory safety pharmacology: a new safety paradigm to de-risk drug candidates prior to selection for regulatory science investigations.An introduction to QT interval prolongation and non-clinical approaches to assessing and reducing riskQTc interval prolongation by d-propoxyphene: what about other analgesics?Improvement of cardiac efficacy and safety models in drug discovery by the use of stem cell-derived cardiomyocytes.An overview of QT interval assessment in safety pharmacology.Translating QT interval prolongation from conscious dogs to humans.Pharmacokinetic-pharmacodynamic modelling of drug-induced QTc interval prolongation in man: prediction from in vitro human ether-à-go-go-related gene binding and functional inhibition assays and conscious dog studies.Cyamemazine metabolites: effects on human cardiac ion channels in-vitro and on the QTc interval in guinea pigs.Pharmacological and electrophysiological characterization of nine, single nucleotide polymorphisms of the hERG-encoded potassium channel.Taxifolin Glycoside Blocks Human ether-a-go-go Related Gene K(+) Channels.Evidence for a crucial modulating role of the sodium channel in the QTc prolongation related to antipsychotics.An overview of QT interval assessment in safety pharmacology.Modelling of drug-induced QT-interval prolongation: estimation approaches and translational opportunities.Discovery of a Potent and Orally Bioavailable CCR2 and CCR5 Dual Antagonist.In Vitro and In Silico Risk Assessment in Acquired Long QT Syndrome: The Devil Is in the Details.Patch-clamp studies of human cardiac ion channels in the evaluation of cardiac electrophysiological effects of compounds.Verapamil blocks HERG channel by the helix residue Y652 and F656 in the S6 transmembrane domain.Effects of Gender on Electrocardiography in Subjects with Shortened Ventricular Depolarization (QRS).
P2860
Q24616403-ABEC76F1-19A5-49C1-B7CC-F6386DDB90AAQ30977143-1CB8C8B7-92D7-493F-AF1B-78E607A1C509Q33185132-7306C8B5-2EE2-469E-ABCF-B2838AF9B339Q34156425-8FBF9359-22FA-4BF6-B110-353932CE6D76Q34241023-578BC7D0-2589-402F-908C-2DAE65F50DA5Q34392292-7C923A83-C884-48E3-8A1F-6D00D9F9C3E2Q34505695-52C67F09-AEAB-4780-AEA4-91A3F05D5234Q34628573-DE213FFD-D0C5-4569-9C14-4E76D64746D0Q35034866-EE2A648F-C4FC-4EA6-8165-DDBDF387E5C1Q35194419-597B75FF-4D86-43D5-9289-0A1589CDE8CDQ35844551-922605B2-23B1-473E-B309-D7EB2F839FD4Q36150565-4BA5B722-D3C1-499A-A8A2-5F09AFCF4EEFQ37369309-44D527F5-3FFA-404D-8387-74968CAE342EQ37527211-79AD546C-2A33-4301-9EA6-5CDAFAB60F15Q37649640-9B9FE000-99ED-45A7-8CF9-19C06D03E840Q37689202-9281C0B2-237B-45C1-8A2C-079516DB1ACCQ38008460-4F01E72E-A0CE-4D11-AFF9-7A779EE7FA54Q38088809-3A3C6653-2C52-42A6-AC06-DBBBEF72DC18Q38112653-2DF6C9AB-602B-4303-885F-56A0D222B7FEQ39404396-C89E892F-5F4A-4861-A43C-08F158FEAD84Q39592121-3C86B5E0-8E2A-4E2E-A366-4768A2C51646Q39924256-9C5A8D54-5781-4182-B4F5-425C359F1B55Q41819839-1812DE0F-84A1-4489-8F6A-026C96241235Q42038642-A9DA1680-0C00-4445-87E8-6126B98F57EDQ45347471-C29858FA-B37C-462F-BCFB-66EECF0D0A1EQ46397243-92D90C16-7D32-47B1-A505-4FDEF90FFF60Q46686425-659DFC93-BB7E-42F4-B4A2-23F5D889A6E5Q46839929-622BD668-A908-4F59-B112-3B0E8F8A687BQ47095257-B2AED333-FE6D-4028-8001-181A4E3F6805Q47753818-DAC0D0D0-2F91-446C-A87E-CB27ECF39684Q48788779-40192B84-0540-4E8A-A924-BF5ADCE6F276Q50989261-03D00B1B-C05C-4E95-9C32-C13BE5EEF4E2
P2860
Drugs that prolong QT interval as an unwanted effect: assessing their likelihood of inducing hazardous cardiac dysrhythmias.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Drugs that prolong QT interval ...... azardous cardiac dysrhythmias.
@ast
Drugs that prolong QT interval ...... azardous cardiac dysrhythmias.
@en
Drugs that prolong QT interval ...... azardous cardiac dysrhythmias.
@nl
type
label
Drugs that prolong QT interval ...... azardous cardiac dysrhythmias.
@ast
Drugs that prolong QT interval ...... azardous cardiac dysrhythmias.
@en
Drugs that prolong QT interval ...... azardous cardiac dysrhythmias.
@nl
prefLabel
Drugs that prolong QT interval ...... azardous cardiac dysrhythmias.
@ast
Drugs that prolong QT interval ...... azardous cardiac dysrhythmias.
@en
Drugs that prolong QT interval ...... azardous cardiac dysrhythmias.
@nl
P2093
P2860
P356
P1476
Drugs that prolong QT interval ...... azardous cardiac dysrhythmias.
@en
P2093
P2860
P304
P356
10.1517/14656566.1.5.947
P407
P577
2000-07-01T00:00:00Z